HUTCHMED· @hutchmed · X·· 3 天前AI 评分42
AI 导读
我们很高兴地宣布，HMPL-A830——一种首创的KRAS-EGFR抗体靶向治疗偶联物（ATTC）——针对不可切除、晚期或转移性实体瘤患者的全球临床试验Ia期部分已启动。https://www.hutch-med.com/hutchmed-gsk-licensing-agreement-kras-egfr-attc/
正文
We are pleased to announce the initiation of the Phase Ia part of a global clinical trial of HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (ATTC), in patients with unresectable, advanced or metastatic solid tumors. https://www.hutch-med.com/hutchmed-gsk-licensing-agreement-kras-egfr-attc/
来源：HUTCHMED · x.com